Sophion and ChanTest Announce Ion Channel Cell Line Collaboration
News Jun 25, 2008
Under the terms of this agreement, Sophion has the right to provide ion channel cell lines from ChanTest that are optimized for Sophion’s QPatch automated patch clamp systems. “We are thrilled to partner with Sophion in the process of optimizing the automated patch clamp world,” said Dr. Arthur “Buzz” Brown, CEO of ChanTest.
“The combination of our extensive ion channel cell line library and Sophion’s QPatch systems is new and has the potential to revolutionize the drug discovery process.”
Dr. Morten Sunesen, Sophion’s Director of Customer Relations, added, “A critical aspect of a thriving QPatch assay relates to having optimized cell lines. This partnership between Sophion and ChanTest allows Pharma and Biotech groups in the ion channel drug discovery industry to quickly get usable data with a great variety of ion channel cell lines.”
The ideal drug is one that only affects the exact cells and neurons it is designed to treat, without unwanted side effects. This concept is especially important when treating the delicate and complex human brain. Now, scientists have revealed a mechanism that could lead to this kind of long-sought specificity for treatments of strokes and seizures.READ MORE